nach oben

Erschienen in:

03.04.2020 | Laboratory Investigation

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma

verfasst von: Sascha Marx, Fabian Wilken, Isabel Wagner, Madlen Marx, Sascha Troschke-Meurer, Maxi Zumpe, Sandra Bien-Moeller, Martin Weidemeier, Joerg Baldauf, Steffen K. Fleck, Bernhard H. Rauch, Henry W. S. Schroeder, Holger Lode, Nikolai Siebert

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Disialoganglioside GD₂ is expressed by glioblastoma multiforme (GBM) cells representing a promising target for anti-GD2 immunotherapeutic approaches. The aim of the present study was to investigate anti-tumor efficacy of the chimeric anti-GD₂ antibody (Ab) dinutuximab beta against GBM.

Methods

Expression levels of GD2 and complement regulatory proteins (CRP; CD46, CD55 and CD59) on well-known and newly established primary tumor originated GBM cell lines were analyzed by flow cytometry. Ab-dependent cellular (ADCC) and complement-dependent cytotoxicity (CDC) mediated by dinutuximab beta against GBM cells were determined by a non-radioactive calcein-AM-based assay.

Results

Analysis of primary GBM cells revealed a heterogeneous GD2 expression that varied between the cell lines analyzed with higher expression levels in the tumor surface compared to the core originated cells. Both GD2-positive and -negative tumor cells were detected in every cell line analyzed. In contrast to CDC, ADCC mediated by dinutuximab beta was observed against the majority of GBM cells. Importantly, CDC-resistant cells showed high expression of the CRP CD46, CD55 and CD59.

Conclusion

Our present data show anti-tumor effects mediated by dinutuximab beta against GBM cells providing a rationale for a GD2-directed immunotherapy against GBM. Due to high CRP expression, a combining of GD2-targeting with CRP blockade might be a further treatment option for GBM.

Arbit E, Cheung NK, Yeh SD, Daghighian F, Zhang JJ, Cordon-Cardo C, Pentlow K, Canete A, Finn R, Larson SM (1995) Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. Eur J Nucl Med 22:419–426. https://doi.org/10.1007/bf00839056 CrossRefPubMed

Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Investig 84:397–405. https://doi.org/10.1038/labinvest.3700070 CrossRefPubMed

Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443–446. https://doi.org/10.1038/74704 CrossRefPubMed

De Felice F, Pranno N, Marampon F, Musio D, Salducci M, Polimeni A, Tombolini V (2019) Immune check-point in glioblastoma multiforme. Crit Rev Oncol Hematol 138:60–69. https://doi.org/10.1016/j.critrevonc.2019.03.019 CrossRefPubMed

Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581–1587. https://doi.org/10.4049/jimmunol.171.3.1581 CrossRefPubMed

Fecci PE, Sampson JH (2019) The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg 131:657–666. https://doi.org/10.3171/2019.5.JNS181762 CrossRefPubMed

Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109–123. https://doi.org/10.1016/s0161-5890(03)00112-3 CrossRefPubMed

Fleurence J, Cochonneau D, Fougeray S, Oliver L, Geraldo F, Terme M, Dorvillius M, Loussouarn D, Vallette F, Paris F, Birkle S (2016) Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget 7:41172–41185. https://doi.org/10.18632/oncotarget.9226 CrossRefPubMedPubMedCentral

Golinelli G, Grisendi G, Prapa M, Bestagno M, Spano C, Rossignoli F, Bambi F, Sardi I, Cellini M, Horwitz EM, Feletti A, Pavesi G, Dominici M (2018) Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. https://doi.org/10.1038/s41417-018-0062-x CrossRefPubMedPubMedCentral

10.

Iwasawa T, Zhang P, Ohkawa Y, Momota H, Wakabayashi T, Ohmi Y, Bhuiyan RH, Furukawa K, Furukawa K (2018) Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2. Int J Oncol 52:1255–1266. https://doi.org/10.3892/ijo.2018.4266 CrossRefPubMed

11.

Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN (2018) Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1617–1629. https://doi.org/10.1016/S1470-2045(18)30578-3 CrossRefPubMed

12.

Ladenstein RL, Poetschger U, Couanet DV, Gray J, Luksch R, Castel V, Ash S, Laureys G, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Popovic MB, Loibner H, Schreier G, Ambros PF, Sarnacki S, Boterberg T, Lode HN (2018) Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls. J Clin Oncol 36:10539–10539. https://doi.org/10.1200/JCO.2018.36.15_suppl.10539 CrossRef

13.

Maenpaa A, Junnikkala S, Hakulinen J, Timonen T, Meri S (1996) Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 148:1139–1152PubMedPubMedCentral

14.

Mennel HD, Bosslet K, Geissel H, Bauer BL (2000) Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors. Exp Toxicol Pathol 52:277–285. https://doi.org/10.1016/S0940-2993(00)80046-9 CrossRefPubMed

15.

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3–K27M(+) diffuse midline gliomas. Nat Med 24:572–579. https://doi.org/10.1038/s41591-018-0006-x CrossRefPubMedPubMedCentral

16.

Platten M, Reardon DA (2018) Concepts for Immunotherapies in Gliomas. Semin Neurol 38:62–72. https://doi.org/10.1055/s-0037-1620274 CrossRefPubMed

17.

Prokazova NV, Kocharov SL, Shaposhnikova GI, Zvezdina ND, Bergelson LD (1984) Changes of glycolipids dependent on cell density of Ehrlich ascites carcinoma cells. Eur J Biochem 141:527–529. https://doi.org/10.1111/j.1432-1033.1984.tb08224.x CrossRefPubMed

18.

Rehman AA, Elmore KB, Mattei TA (2015) The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes. Neurosurg Focus 38:E14. https://doi.org/10.3171/2015.1.FOCUS14742 CrossRefPubMed

19.

Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT (2014) Vaccine therapies for patients with glioblastoma. J Neurooncol 119:531–546. https://doi.org/10.1007/s11060-014-1502-6 CrossRefPubMed

20.

Schengrund CL, Repman MA (1982) Density-dependent changes in gangliosides and sialidase activity of murine neuroblastoma cells. J Neurochem 39:940–947. https://doi.org/10.1111/j.1471-4159.1982.tb11480.x CrossRefPubMed

21.

Siebert N, Seidel D, Eger C, Juttner M, Lode HN (2014) Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. PLoS ONE 9:e107692. https://doi.org/10.1371/journal.pone.0107692 CrossRefPubMedPubMedCentral

22.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

23.

Suzuki M, Cheung NK (2015) Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 19:349–362. https://doi.org/10.1517/14728222.2014.986459 CrossRefPubMed

24.

Weller M, Le Rhun E, Preusser M, Tonn JC, Roth P (2019) How we treat glioblastoma. ESMO Open 4:e000520. https://doi.org/10.1136/esmoopen-2019-000520 CrossRefPubMedPubMedCentral

25.

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. https://doi.org/10.1056/NEJMra0708126 CrossRefPubMed

26.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology G (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324–1334. https://doi.org/10.1056/NEJMoa0911123 CrossRefPubMedPubMedCentral

Titel: GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
verfasst von: Sascha Marx
Fabian Wilken
Isabel Wagner
Madlen Marx
Sascha Troschke-Meurer
Maxi Zumpe
Sandra Bien-Moeller
Martin Weidemeier
Joerg Baldauf
Steffen K. Fleck
Bernhard H. Rauch
Henry W. S. Schroeder
Holger Lode
Nikolai Siebert
Publikationsdatum: 03.04.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03470-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma